1. Japan Stocks

  2. •

    Finance

  3. •

    Real estate development
ADR Biomedical Holdings Inc.

ADR Biomedical Holdings Inc.

TTSE:3750
754.00
JPY
-1.00
(-0.13%)
7.27BMarket Cap
Nov 13Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
686.1
566.96
373.61
381.75
76.89
286.71
175.86
169.63
151.26
240.21
174.77
13.69
5.71
- -
Basic EPS, GAAP
59.36
16.81
4.75
-65.81
66.25
88.3
47.58
-101.64
-8.79
-118.71
15.47
-239.7
-44.46
- -
Free Cash Flow per Basic Share
-156.22
-2.19
-57.63
249.65
37.46
-409.78
77.34
-12.08
-41.66
-22.18
-130.87
-111.46
-87.9
- -
Dividend per Share
- -
- -
- -
- -
- -
10
20
8.2
- -
- -
- -
- -
- -
- -
Book Value per Share
421.42
444.24
449.08
389.15
458.09
536.39
568.06
406.97
415.81
297.1
312.58
70.62
2.47
- -
Tangible Book Value per Share
414.47
438.62
445.03
388.79
457.8
535.86
440.03
315.07
332.65
219.95
310.2
70.4
2.47
- -
Basic Weighted Avg Shares
5
7
7
7
7
7
7
8
9
9
9
9
9
9
Sales/Revenue/Turnover
3,531
4,076
2,684
2,693
522
1,925
1,180
1,388
1,336
2,145
1,560
122
51
- -
Operating Margin (%)
19.72
20.56
-0.66
-14.8
24.98
15.24
-10.94
-52.7
-34.62
-37.04
-49.52
-660.28
-1,777.23
- -
Depreciation Expense
77
68
17
9
10
50
174
308
321
331
254
50
1
- -
Net Income, GAAP
306
121
34
-464
450
593
319
-832
-78
-1,060
138
-2,140
-397
- -
Effective Tax Rate (%)
- -
42
54.93
- -
0.41
0.26
0.58
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
8.65
2.96
1.27
-17.24
86.16
30.8
27.06
-59.92
-5.81
-49.42
8.85
-1,751.24
-778.43
- -
Working Capital
2,524
2,952
3,161
2,680
873
6,370
5,667
5,535
2,034
215
892
25
124
- -
LT Debt
- -
- -
- -
- -
- -
2,890
8,219
8,013
8,551
7,606
2,347
2,294
- -
- -
Total Equity
3,031
3,193
3,226
2,717
3,075
3,601
3,833
3,548
3,716
2,657
2,796
631
22
- -
Return on Invested Capital (%)
- -
7.28
-3.08
- -
3.25
4.81
-1.32
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
3.9
1.06
- -
11.45
10.36
3.89
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
12.68
3.88
1.06
-15.62
15.54
17.76
8.62
-22.61
-2.14
-33.3
5.08
-125.1
-121.64
- -

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
50
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
9
9
Market Capitalization
7,875
7,267
6,946

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
574
351
- -
Cash, Cash Equivalents & STI
290
126
- -
Accounts Receivable, Net
6
8
- -
Inventories
63
66
- -
Total Current Liabilities
197
227
- -
Payables & Accruals
- -
- -
- -
ST Debt
50
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-17.9%
-38.5%
-96.51%
Free Cash Flow
-135%
136%
-21.14%
Net Income, GAAP
-270.1%
-133.78%
-81.45%
Sales/Revenue/Turnover
4.63%
-24.18%
-58.28%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
122
2026
- -
- -
- -
- -
51
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
-239.7
2026
- -
- -
- -
- -
-44.46
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yoshihiro Hoshino
Full Time Employees
13
Sector
Finance
Industry
Real estate development
Address
FDC Kojimachi Building Tokyo TY Japan 102-0083
IPO Date
Oct 1, 2004
Website
adr.co.jp
Similar Companies
DLF Limited (NSE:DLF)
Opendoor Technologies Inc (NASDAQ:OPEN)
Samolet (MOEX:SMLT)
Alarko Holding A.S. (BIST:ALARK)
Godrej Properties Limited (NSE:GODREJPROP)
Lodha Developers Ltd. (NSE:LODHA)
Business
ADR120S, Inc. (TSE: 3750) develops, produces and sells adipose-derived regenerative cell (ADRC) therapy medical devices and related technology in Japan; core products include the Celusion centrifuge and Celusion cell therapy kits; product pipeline features ECCI-50 for male stress urinary incontinence and liver cirrhosis, Cyt-006 to prevent postoperative adhesion in primary rectal cancer, alongside clinical research in anterior cruciate ligament repair, bone repair, burn scars, chronic wound healing, critical limb ischemia, anal and Crohn's disease fistulas, and erectile dysfunction. Incorporated in 2004 and headquartered in Tokyo, the company operates through Medical and Real Assets segments, with the latter focused on real estate investment, purchase and sales, hotel development, brokerage services, and property management. Recent developments include a name change from Cytori Cell Research Institute Inc., memoranda of understanding with China's Weilin Group and state-owned Guangcai Group for business collaboration, an exclusive license for high-concentration exosome production technology, establishment of subsidiaries including one in Saudi Arabia, a share transfer agreement on October 29, 2025 to acquire 71.51% of AthleteMed Corporation from EBISTRADE Inc., and sales of hospitality assets such as Fractal Hospitality Co. and Hotel Kanazawa Co. to Samty Hotel Management K.K. in 2024.